Suchen
Ultragenyx Pharmaceutical Inc
RAREZur Watchlist hinzufügen
32.875USD
-0.515-1.54%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
3.23BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Ultragenyx Pharmaceutical Inc Unternehmen
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Ultragenyx Pharmaceutical Inc Informationen
BörsenkürzelRARE
Name des UnternehmensUltragenyx Pharmaceutical Inc
IPO-datumJan 31, 2014
CEOKakkis (Emil D)
Anzahl der mitarbeiter1294
WertpapierartOrdinary Share
GeschäftsjahresendeJan 31
Addresse60 Leveroni Ct
StadtNOVATO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94949
Telefon14154838800
Websitehttps://www.ultragenyx.com/
BörsenkürzelRARE
IPO-datumJan 31, 2014
CEOKakkis (Emil D)
Führungskräfte von Ultragenyx Pharmaceutical Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.83M
+2.71%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
140.45K
+16.46%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
90.60K
+31.89%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
44.07K
-10.56%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
34.70K
+22.34%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
34.70K
+22.34%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
25.38K
+30.54%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
22.21K
+9.05%
Mr. Matthew K. (Matt) Fust
Mr. Matthew K. (Matt) Fust
Independent Director
Independent Director
--
--
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.83M
+2.71%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
140.45K
+16.46%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
90.60K
+31.89%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
44.07K
-10.56%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
34.70K
+22.34%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
34.70K
+22.34%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Ultragenyx Pharmaceutical Inc?
Die fünf größten Anteilseigner von Ultragenyx Pharmaceutical Inc sind: Dr. Emil D. Kakkis, M.D., Ph.D.
Wie viele Institutionen halten Anteile an Ultragenyx Pharmaceutical Inc (RARE)?
Mit Stand vom 2026Q1 halten 695 Institutionen Anteile an Ultragenyx Pharmaceutical Inc, mit einem Gesamtmarktwert von etwa 106.19M, was 107.82% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1315399.00 gestiegen.
Was ist die größte Einnahmequelle von Ultragenyx Pharmaceutical Inc?
Am 2026Q1 erzielte das Geschäft mit Crysvita royalty revenue für Ultragenyx Pharmaceutical Inc den höchsten Umsatz in Höhe von 304.00M, was 45.17% des Gesamtumsatzes entspricht.